Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094328 · ClinicalTrials.gov registry record · Phase 2
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
A Phase 2 study of Puberty, Precocious, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 15
- Study locations
NCT00094328 is a Phase 2 study of Puberty, Precocious that has completed, run by AstraZeneca. The registered enrollment target is 14 participants. The trial reports 15 study locations across 11 states.
The verdict
NCT00094328, a Phase 2 study of Puberty, Precocious, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG Bicalutamide
Study Locations (15)
Other
- Research Site - Montpellier
- Research Site - Chennai
- Research Site - New Dehli
- Research Site - Moscow
- Research Site - London
Alabama
- Research Site - Birmingham
Florida
- Research Site - Jacksonville
Indiana
- Research Site - Indianapolis
Minnesota
- Research Site - Minneapolis
Oklahoma
- Research Site - Tulsa
Pennsylvania
- Research Site - Philadelphia
South Carolina
- Research Site - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-11-22 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094328
The ClinicalTrials.gov registry entry for NCT00094328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Puberty, Precocious appearing as the primary indexed condition, and to 2 interventions - of which Anastrozole is the first listed.
NCT00094328 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Other, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00094328 about?
NCT00094328 is a clinical study titled "Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]". The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of mu...
What is the current status of trial NCT00094328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2004-11-22. Estimated completion is 2017-12-06.
What conditions does trial NCT00094328 study?
This clinical trial studies the following conditions: Puberty, Precocious.
What interventions are being tested in trial NCT00094328?
The interventions under investigation include: Anastrozole (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00094328?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094328 being conducted?
This trial has 15 study locations across Alabama, Florida, Indiana, Minnesota, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Puberty, Precocious
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.